Search

Displaying results 1701 - 1710 of 4539 in total
  1. Drug

    MK-0777

    go.drugbank.com/drugs/DB12238
    Investigational

    MK-0777 has been used in trials studying the treatment of Schizophrenia, Anxiety Disorder, and Generalized Anxiety Disorder.

  2. Drug

    Ertugliflozin

    go.drugbank.com/drugs/DB11827
    ApprovedInvestigational

    [A31581] Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.[L48621]

  3. Drug

    Clozapine

    go.drugbank.com/drugs/DB00363
    ApprovedInvestigational

    [A256718] Clozapine was approved by the FDA in 1989 for treatment-resistant schizophrenia under the brand CLOZARIL.

  4. Drug

    Histidine

    go.drugbank.com/drugs/DB00117
    ApprovedInvestigationalNutraceutical

    An essential amino acid that is required for the production of histamine.

    Mixtures: PF K-CAMINE %8 AMINO ASIT IV INFUZYON ICIN COZELTI, 500 ML (SETLI), PF K-CAMINE %8 AMINO ASIT IV INFUZYON ICIN COZELTI, 1000 ML (SETLI)
  5. Drug

    Varespladib methyl

    go.drugbank.com/drugs/DB05737
    Investigational

    Varespladib methyl has been investigated for the treatment of Acute Coronary Syndrome. Studies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.

  6. Drug

    Trioxsalen

    go.drugbank.com/drugs/DB04571
    ApprovedWithdrawn

    It is administered either topically or orally in conjunction with UV-A (the least damaging form of ultraviolet light) for phototherapy treatment of vitiligo and hand eczema.

  7. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    Endogenous VWF protects FVIII from degradation but also sets a half-life of approximately 15 to 19 h. … [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414]

  8. Drug

    Certolizumab pegol

    go.drugbank.com/drugs/DB08904
    ApprovedInvestigational

    [A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819]

  9. Drug

    trans NV-04

    go.drugbank.com/drugs/DB05843
    Experimental

    trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.

  10. Drug

    Ciforadenant

    go.drugbank.com/drugs/DB16125
    Investigational

    Ciforadenant is under investigation in clinical trial NCT02253745 (Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)).